Head-to-Head Metric Comparison
| Clinical Parameter | Topical 5% ET-02 (First-in-Human / Phase 1) | Topical Minoxidil 5% (Standard Benchmark) | Low-Dose Oral Minoxidil (1.25–5 mg) |
| Primary Biological Mechanism | Restores inactive/dormant hair follicle stem cells and activates melanocyte progenitors. | Opens ATP-sensitive potassium ($K_{ATP}$) channels; promotes microvascular perfusion. | Systemic $K_{ATP}$ channel opening and non-specific vasodilation. |
| Response Window | 28 to 35 days (4 to 5 weeks). | 16 to 24 weeks (4 to 6 months). | 12 to 24 weeks (3 to 6 months). |
| Short-Term Non-Vellus Hair Count | 6-fold increase versus vehicle placebo at week 5. | Often flat or negative at week 4 due to the telogen shed. | Often flat or negative at week 4 due to the telogen shed. |
| Relative Hair Growth Velocity | One month of ET-02 produced greater net hair growth than 16 weeks of topical minoxidil in comparative trial datasets. | Standard slow-ramp trajectory; peaks between months 6 and 12. | Moderate-ramp trajectory; peaks between months 6 and 12. |
| Hair Shaft Caliber Impact | Early shaft widening measurable via trichoscopy by Day 28. | Caliber expansion typically requires 3 to 6 months. | Caliber expansion typically requires 3 to 6 months. |
| Pigmentation & Graying | Concurrently stimulates follicular melanin production in emerging shafts. | Zero effect on melanogenesis or canities (graying). | Zero effect on melanogenesis or canities (graying). |
| Key Limiting Factors | Early-stage data (Phase 1/first-in-human; small cohort, $n=24$). | Dependent on scalp sulfotransferase (SULT1A1) enzyme activity. | Cardiovascular monitoring required (reflex tachycardia, fluid retention). |
Why the 28-Day Timeline Outpaces Minoxidil
-
Bypassing the Telogen “Dumping” Phase: Standard minoxidil forces resting telogen follicles to abruptly shed before new fibers can form, which is why users frequently experience a heavy initial shedding period during weeks 2 through 6. ET-02 activates dormant hair follicle stem cells directly in place, accelerating progenitor proliferation without precipitating a massive telogen washout.
-
Enzyme Independence: Up to 60% of people respond poorly to topical minoxidil because their scalp lacks sufficient levels of the enzyme sulfotransferase (SULT1A1), which is required to convert minoxidil into its active form. ET-02 is an active small molecule that functions independently of sulfotransferase, bypassing this common point of treatment failure.
-
Follicular Canal Remodeling: Digital trichoscopy from the trial indicated that ET-02 rapidly widens the follicular infundibulum, allowing miniaturized hairs to emerge as thicker, non-vellus fibers early in the growth cycle.
The primary caveat remains sample size: the 28-day data comes from an exploratory first-in-human cohort ($n=24$). The planned six-month Phase 2 trial launching in 2027 will determine whether this initial rate of growth compounds over time or levels off into a plateau.